©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2026; 17(2): 116390
Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116390
Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116390
Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies
Chuang Cai, Department of Cancer Research Institute of Zhongshan, Zhongshan People’s Hospital, Zhongshan 528445, Guangdong Province, China
Jin-Man Chen, Department of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China
Zu-Xun Qiu, Shu-Qi Ren, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, Zhongshan 528467, Guangdong Province, China
Co-first authors: Chuang Cai and Jin-Man Chen.
Author contributions: Cai C and Chen JM contributed to the work equally and are co-first authors of this manuscript; Cai C and Chen JM conceived the review and drafted the initial manuscript; Cai C, Chen JM, Qiu ZX, and Ren SQ made substantial contributions to this manuscript; Chen JM and Qiu ZX were responsible for literature collation; Cai C and Ren SQ edited and finalized the manuscript for submission; and all authors reviewed and approved the submitted manuscript.
Supported by Zhongshan Science and Technology Bureau, No. 2023B1033.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shu-Qi Ren, Associate Research Scientist, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, No. 10 Dexiu Road, Zhongshan 528467, Guangdong Province, China. shuchijen@163.com
Received: November 11, 2025
Revised: December 1, 2025
Accepted: December 24, 2025
Published online: February 24, 2026
Processing time: 87 Days and 24 Hours
Revised: December 1, 2025
Accepted: December 24, 2025
Published online: February 24, 2026
Processing time: 87 Days and 24 Hours
Core Tip
Core Tip: This editorial focuses on the expression and clinical importance of the tight junction protein claudin-6 (CLDN6) in high-grade endometrial carcinoma. It demonstrates that CLDN6 overexpression independently correlates with aggressive pathological characteristics and poor patient outcomes. These findings underscore CLDN6’s value as a prognostic biomarker and highlight its potential as a therapeutic target, opening new possibilities for improved risk stratification and personalized treatment strategies in high-grade endometrial carcinoma.